Tìm theo
Basiliximab
Các tên gọi khác (2) :
  • chimeric mouse-human antiCD25
  • Ig gamma-1 chain C region
Thuốc chống ung thư và tác động vào hệ thống miễn dịch
Thuốc Gốc
Biotech
CAS: 152923-56-3
ATC: L04AC02
ĐG : Novartis AG , http://www.novartis.com
CTHH: C6378H9844N1698O1997S48
PTK: 143801.3000
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6378H9844N1698O1997S48
Phân tử khối
143801.3000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.473
Điểm đẳng điện tích
8.68
Dược Lực Học : Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Cơ Chế Tác Dụng : A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha. Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.
Dược Động Học :

▧ Volume of Distribution :
* 7.8 ± 5.1 L [Pediatric] * 4.8 ± 2.1 L [Adult]
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes, or by human antimurine antibody production
▧ Half Life :
7.2 +/- 3.2 days (adults)
▧ Clearance :
* 41 +/- 19 mL/h [Adult patients undergoing first kidney transplantation] * 17 +/- 6 mL/h [pediatric patients undergoing renal transplantation] * 31 +/- 19 mL/h [adolescent patients undergoing renal transplantation]
Chỉ Định : For prophylactic treatment of kidney transplant rejection
Tương Tác Thuốc :
  • Canakinumab results in increased immunosuppressive effects; increases the risk of infection.
  • Rilonacept results in increased immunosuppressive effects; increases the risk of infection.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Simulect 10 mg vial
    Giá bán buôn : USD >1883.11
    Đơn vị tính : vial
  • Biệt dược thương mại : Simulect 20 mg vial
    Giá bán buôn : USD >2471.6
    Đơn vị tính : vial
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00074
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0078-0393-61
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA164747126
Wikipedia
http://en.wikipedia.org/wiki/Basiliximab
RxList
http://www.rxlist.com/cgi/generic2/basiliximab.htm
Drugs.com
http://www.drugs.com/cdi/basiliximab.html
... loading
... loading